Cargando…

Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

SIMPLE SUMMARY: This paper presents a paradigm-shifted approach for adverse event (AE) analysis from classic descriptive summary into modern informative statistics to fulfill precision medicine. It defines early AE and derives a series of innovative AE biomarkers to assess grade, treatment relatedne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Dung-Tsa, Saltos, Andreas N., Rose, Trevor, Thompson, Zachary J., Thapa, Ram, Chiappori, Alberto, Gray, Jhanelle E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177532/ https://www.ncbi.nlm.nih.gov/pubmed/37173987 http://dx.doi.org/10.3390/cancers15092521

Ejemplares similares

Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer
por: Chen, Dung-Tsa, et al.
Publicado: (2021)

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
por: Chiappori, Alberto A., et al.
Publicado: (2018)

Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer
por: Tanvetyanon, Tawee, et al.
Publicado: (2023)

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)

A Bayesian pick-the-winner design in a randomized phase II clinical trial
por: Chen, Dung-Tsa, et al.
Publicado: (2017)

Strategies for power calculations in predictive biomarker studies in survival data
por: Chen, Dung-Tsa, et al.
Publicado: (2016)

Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
por: Chen, Lu, et al.
Publicado: (2016)

Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial
por: Chen, Dung-Tsa, et al.
Publicado: (2019)

Gastrointestinal adverse events of immunotherapy
por: Cappello, Giovanni, et al.
Publicado: (2021)

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
por: Albarrán-Artahona, Víctor, et al.
Publicado: (2022)

Clinical associations of mucin 1 in human lung cancer and precancerous lesions
por: Saltos, Andreas, et al.
Publicado: (2018)

Adverse Events of Oncologic Immunotherapy and Their Management
por: Barber, Fedricker Diane
Publicado: (2019)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

Rheumatological Adverse Events Following Immunotherapy for Cancer
por: Cretu, Ioana, et al.
Publicado: (2022)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

Immune-related adverse events of biological immunotherapies used in COVID-19
por: Baracaldo-Santamaría, Daniela, et al.
Publicado: (2022)

Understanding adverse events of immunotherapy: A mechanistic perspective
por: Burke, Kelly P., et al.
Publicado: (2020)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
por: Rahman, Md. Mominur, et al.
Publicado: (2022)

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy
por: Hu, Wei-Ting, et al.
Publicado: (2023)

Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer
por: Ni, Jun, et al.
Publicado: (2021)

Plasma Cell‐Free DNA Genotyping: From an Emerging Concept to a Standard‐of‐Care Tool in Metastatic Non‐Small Cell Lung Cancer
por: Gray, Jhanelle, et al.
Publicado: (2021)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy
por: Exley, Christopher
Publicado: (2014)

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
por: Morimoto, Kenji, et al.
Publicado: (2021)

Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer
por: Puri, Sonam, et al.
Publicado: (2020)

Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
por: Dora, David, et al.
Publicado: (2023)

Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer
por: Tunali, Ilke, et al.
Publicado: (2021)

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management
por: Stucci, Stefania, et al.
Publicado: (2017)

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
por: van Holstein, Yara, et al.
Publicado: (2019)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with Glucocorticoids
por: Manzo, Ciro, et al.
Publicado: (2018)

Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer
por: Green, Hannah Elizabeth, et al.
Publicado: (2021)

The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
por: Gao, Weitong, et al.
Publicado: (2023)

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
por: Kunimasa, Kei, et al.
Publicado: (2020)

Evaluation of adverse events in small‐breed dogs treated with maropitant and a single dose of doxorubicin
por: Matsuyama, Fukiko, et al.
Publicado: (2022)

Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
por: Negishi, Akio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_56nhb8go22ud64u6l8s1okss2p